DEA Proposes Reclassifying Dual Orexin Antagonists to Schedule V
Event summary
- The DEA proposed reclassifying dual orexin receptor antagonists from Schedule IV to Schedule V, citing lack of physical or psychological dependence.
- Public comments on the proposal will be accepted for 30 days starting August 11, 2026.
- Idorsia's daridorexant (QUVIVIQ) is approved in the US for chronic insomnia treatment.
The big picture
The DEA's proposal reflects growing recognition of dual orexin antagonists as safer alternatives to existing sleep medications. This shift could accelerate adoption of Idorsia's QUVIVIQ, particularly if the reclassification is finalized. The move aligns with broader industry trends toward less restrictive scheduling for drugs with favorable safety profiles.
What we're watching
- Regulatory Timeline
- The pace at which the DEA finalizes the reclassification will determine how quickly Idorsia can capitalize on expanded patient access.
- Market Response
- How investors react to this potential de-risking of Idorsia's lead insomnia treatment.
- Competitive Positioning
- Whether this reclassification gives Idorsia a meaningful advantage over traditional sedative-hypnotics in the insomnia market.
Related topics